Trial reportThe oncologist2026
Resilience in symptom response to cancer treatment: a new lens for examining variable symptom trajectories in older adults with advanced cancer.
Trial report in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02054741 (A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults
Who cites it
1 citing paper in PubMed.
- The indirect association between psychological resilience and prosocial behavior through cognitive reappraisal in Chinese college students.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSymptom trajectories vary among patients during cancer treatment. The National Institutes of Health resilience model, which defines resilience as the ability to resist, recover, or grow from stressors, may be useful in understanding these variations. This study examined variations in symptom trajectories through the lens of resilience among older adults with advanced cancer.
methodsThis longitudinal quantitative study included patients aged 70 and older with advanced cancer who were receiving treatment regimens associated with a high risk of treatment-related toxicities, using data from the GAP70+ study (NCT02054741). A summary severity score of 24 symptoms from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events and functional status (measured by instrumental activities of daily living) were assessed prior to the treatment regimen initiation, at 4-6 weeks, 3 months, and 6 months later. Symptom trajectories were estimated using growth mixture models. Resilience was indicated by trajectories of resisting, recovering, or growing (ie, improving from moderate/severe to none/mild severity). Its association with functional status was examined using longitudinal linear mixed models.
resultsThe study included 710 patients (average age 77.2, 43.2% female, 88.0% receiving chemotherapy). Overall, 17.7% of patients showed resilience in symptom response, which was associated with higher baseline functional status (13.2 vs 12.0, P <.001) and stable functioning over 6 months. In contrast, non-resilience in symptom response was associated with a functional decline of 0.7-0.9 points without recovery by 6 months (P<.001).
conclusionResilience in symptom response provides a novel perspective on symptom trajectory variations. Future research should explore underlying contributing factors to inform interventions that promote resilient symptom responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.